Evidence map›Paper›PMID 31785610›Full record

ArticleJournal of neuroinflammation2019

Anti-MOG autoantibodies pathogenicity in children and macaques demyelinating diseases.

Che Serguera, Lev Stimmer, Claire-Maelle Fovet, Philippe Horellou, Vanessa Contreras, Nicolas Tchitchek, Julie Massonneau, Carole Leroy, Audrey Perrin, Julien Flament and 9 more

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 8 institutions in 2 countries.

Che SergueraCommissariat à l'Energie Atomique (CEA), Institut de biologie François Jacob, Molecular Imaging Research Center (MIRCen), 92265, Fontenay-aux-Roses, France. che.serguera-y-lagache@inserm.fr.ORCID http://orcid.org/0000-0002-9210-0636
Lev StimmerCommissariat à l'Energie Atomique (CEA), Institut de biologie François Jacob, Molecular Imaging Research Center (MIRCen), 92265, Fontenay-aux-Roses, France.
Claire-Maelle FovetCommissariat à l'Energie Atomique (CEA), Institut de biologie François Jacob, Molecular Imaging Research Center (MIRCen), 92265, Fontenay-aux-Roses, France.
Philippe HorellouCEA, Inserm UMR 1184 and Institut de biologie François Jacob, Infectious Diseases Models for Innovative Therapies (IDMIT), Université Paris-Sud, 92265, Fontenay-aux-Roses, France.
Vanessa ContrerasCEA, Inserm UMR 1184 and Institut de biologie François Jacob, Infectious Diseases Models for Innovative Therapies (IDMIT), Université Paris-Sud, 92265, Fontenay-aux-Roses, France.
Nicolas TchitchekCEA, Inserm UMR 1184 and Institut de biologie François Jacob, Infectious Diseases Models for Innovative Therapies (IDMIT), Université Paris-Sud, 92265, Fontenay-aux-Roses, France.
Julie MassonneauCommissariat à l'Energie Atomique (CEA), Institut de biologie François Jacob, Molecular Imaging Research Center (MIRCen), 92265, Fontenay-aux-Roses, France.
Carole LeroyAssistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Pediatric Neurology Department, National Referral Center for Rare Inflammatory Brain and Spinal Diseases, Hôpitaux Universitaires Paris-Sud, Paris, France.
Audrey PerrinCEA, Inserm UMR 1184 and Institut de biologie François Jacob, Infectious Diseases Models for Innovative Therapies (IDMIT), Université Paris-Sud, 92265, Fontenay-aux-Roses, France.
Julien FlamentCommissariat à l'Energie Atomique (CEA), Institut de biologie François Jacob, Molecular Imaging Research Center (MIRCen), 92265, Fontenay-aux-Roses, France.
Philippe HantrayeCommissariat à l'Energie Atomique (CEA), Institut de biologie François Jacob, Molecular Imaging Research Center (MIRCen), 92265, Fontenay-aux-Roses, France.
Joanna DemillyCommissariat à l'Energie Atomique (CEA), Institut de biologie François Jacob, Molecular Imaging Research Center (MIRCen), 92265, Fontenay-aux-Roses, France.
Romain MarignierHôpital Neurologique Pierre Wertheimer, Service de Neurologie, Sclérose en plaques, pathologies de la myéline et neuro-inflammation, CHU de Lyon, 69677, Bron Cedex, France.
Pascale ChrétienImmunology Department AP-HP, Hôpitaux Universitaires Paris-Sud, Le Kremlin Bicêtre, France.
Bert't HartDepartment of Immunobiology, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands.
Jean BoutonnatCHU Grenoble-Alpes - TIMC UMR CNRS 5525, Grenoble, France.
Clovis AdamLab. de Neuropathologie, GHU Paris-Sud - Hopital Bicêtre, 94270, Le Kremlin Bicêtre, France.
Roger Le-GrandCEA, Inserm UMR 1184 and Institut de biologie François Jacob, Infectious Diseases Models for Innovative Therapies (IDMIT), Université Paris-Sud, 92265, Fontenay-aux-Roses, France.
Kumaran DeivaCEA, Inserm UMR 1184 and Institut de biologie François Jacob, Infectious Diseases Models for Innovative Therapies (IDMIT), Université Paris-Sud, 92265, Fontenay-aux-Roses, France.
Université Paris-Sud · FRInserm · FRCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRAssistance Publique – Hôpitaux de Paris · FRBicêtre Hospital · FRCentre National de la Recherche Scientifique · FRObservatoire Français de la Sclérose en Plaques · FRUniversity Medical Center Groningen · NL

Funding

Commissariat à l'Énergie Atomique et aux Énergies Alternatives 0200INSERM 00100
6 · The paper itself

Abstract

backgroundAutoantibodies against myelin oligodendrocyte glycoprotein (anti-MOG-Abs) occur in a majority of children with acquired demyelinating syndromes (ADS) and physiopathology is still under investigation. As cynomolgus macaques immunized with rhMOG, all develop an experimental autoimmune encephalomyelitis (EAE), we assessed relatedness between anti-MOG-Abs associated diseases in both species.

methodsThe study includes 27 children followed for ADS and nine macaques with rhMOG-induced EAE. MRI lesions, cytokines in blood, and CSF at onset of ADS or EAE, as well as histopathological features of brain lesions were compared.

resultsTwelve children with anti-MOG-Abs ADS (ADS MOG+) and nine macaques with EAE, presented increased IL-6 and G-CSF in the CSF, whereas no such signature was found in 15 ADS MOG-. Furthermore, IgG and C1q were associated to myelin and phagocytic cells in brains with EAE (n = 8) and in biopsies of ADS MOG+ (n = 2) but not ADS MOG- children (n = 1). Macaque brains also revealed prephagocytic lesions with IgG and C1q depositions but no leukocyte infiltration.

conclusionsChildren with ADS MOG+ and macaques with EAE induced with rhMOG, present a similar cytokine signature in the CSF and a comparable aspect of brain lesions indicating analogous pathophysiological processes. In EAE, prephagocytic lesions points at IgG as an initial effector of myelin attack. These results support the pertinence of modeling ADS MOG+ in non-human primates to apprehend the natural development of anti-MOG-associated disease, find markers of evolution, and above all explore the efficacy of targeted therapies to test primate-restricted molecules.

Indexed as

AdolescentAnimalsAutoantibodiesChildChild, PreschoolDemyelinating DiseasesEncephalomyelitis, Autoimmune, ExperimentalFemaleHumansMacacaMaleMyelin-Oligodendrocyte GlycoproteinAutoantibodiesMyelin-Oligodendrocyte GlycoproteinAnti-MOG IgGBrain inflammationComplementCSFCytokinesDemyelination

Identifiers

PMID31785610
PMCPMC6884758
OpenAlexW2994068060

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.